Gemcitabine plus capecitabine has modest activity in the treatment of metastatic renal cancer refractory to or unsuitable for immunotherapy

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1470, 2005-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Capecitabine, oxaliplatin plus erlotinib is promising for the treatment of metastatic colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1538, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Gemcitabine plus docetaxel `has moderate activity' in advanced pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1281, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Capecitabine plus paclitaxel in metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Lenalidomide has demonstrated antitumour activity in patients with metastatic renal cancer

By  

Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite